178th iCeMS Seminar: Dr. Tsuneaki Sakata, Dr. Sotirios Karathanasis, Mr Joydeep Goswami, Dr Colin Wilde, Mr Niall Duxbury
Dr. Tsuneaki Sakata
Shionogi Science Program: an industry-academic initiative
for open innovation in pharmaceutical industry
Shionogi has a long history of building partnerships and collaborating with
researchers in areas of interest and unmet medical need. As part of this wider
goal, the Shionogi Science Program (SSP) was launched in the UK in 2011
following the success of the Japanese initiative FINDS (PHarma-INnovation
Discovery competition Shionogi) which was founded in 2007. Shionogi's presence
in Europe is growing and last year the SSP expanded to Australia, Belgium,
Denmark, France, Germany, Ireland, Luxembourg and the Netherlands.
Dr. Sotirios Karathanasis
Industry-academia collaborations: current trends and issues
to overcome and opportunities offered by breakthroughs in
stem cell biology and regenerative medicine
Although a variety of factors contribute to the productivity decline of the Pharmaceutical
Industry (Pharma) in recent years, the declining ability to innovate is
thought to play a fundamental role. This, so called "innovation deficit", occurs
in the background of an accelerated pace of innovation in Academia. I will
discuss possible factors responsible for this "innovation deficit" in Pharma and I
will focus on elements that might prevent Academic innovations from effective
translocation, internalization, and translation into new drug Discovery and
Development projects in Pharma. I will emphasize the unique opportunities
that recent breakthroughs in stem cell biology and regenerative medicine offer
in this context.
Mr Joydeep Goswami
Alternative models for Industry Academia partnerships
As science gets more complicated and industry's appetite for risk is reduced due
to financial pressures, industry academic collaborations are becoming more
frequent and several new models are emerging. These models have evolved from
the simple licensing and sponsored research models, to more complex ones that
provide the ability to flex between custom projects for customers to longer term
technology development collaborations. In some of these cases, governments
are also helping fund these collaborations adding additional options to these
relationships. The talk will discuss some of these models in more depth.
Dr Colin Wilde
Scottish Model for Industry Academia collaboration:
Human Primary and Stem Cell-Based Analysis in Preclinical
Drug Discovery
Clinical therapy is being revolutionised by regenerative medicine and cell
therapy, driven by advances in human cell biology. The same advances offer
prospect of a step-change in therapeutic discovery, through introduction of
highly-predictive preclinical cell-based analysis, which will reduce drug attrition
in late-stage development and contribute substantially to healthcare economics
through efficiency gains during new therapeutic development. This talk reviews
human cell culture technologies leading this step-change, from cell banking to
complex cell model development and the opportunities to apply advanced
manufacturing technology in scalable production of user-friendly screening
platforms. Technology development is illustrated by examples of industryacademia
partnerships arising from AvantiCell Science's active engagement in
national and pan-European research consortia.
Mr Niall Duxbury
Scottish model for Industry Academia collaboration for
Innovative microarray solutions, powered by inkjet technology
Arrayjet, the inkjet microarray company, is the leading provider of inkjet microarray
solutions to the biotech industry, academic researchers, and diagnostic companies
worldwide. We offer a flexible, customer focussed contract service
through Arrayjet Advance™, and an established range of scalable microarray
instruments, maintenance support, accessories & consumables. Arrayjet's inkjet
printing platform is most commonly used for rapid printing of microarrays
including DNA, protein, cell lysates, serum and nanoparticles, but it has also been
used to deliver reagents for non-microarray applications such as miniaturised
PCR, lab on a chip and MEMS devices. More recently we have been approached
to explore capabilities in cell printing and reverse transfection for stem cell differentiation,
an area we are keen to expand. The patented technology utilises a
unique combination of a multi-nozzle inkjet printhead (Xaar XJ126) with the
JetSpyder™ which automates loading of samples into the printhead. The industrial
standard printhead offers enhanced reproducibility, speed and ease of use,
whilst preventing nozzle clogging.
| Lecturer |
Dr. Tsuneaki Sakata Senior Fellow, Global Innovation Office, Shionogi & Co, Ltd Dr. Sotirios Karathanasis Executive Director, Cardiovascular and Metabolic Diseases, MedImmu Mr. Joydeep Goswami Chief Scientist, Cellular Sciences, Life Sciences, GE Healthcare Dr. Colin Wilde Chief Scientist, Cellular Sciences, Life Sciences, GE Healthcare Mr. Niall Duxbury Distribution Manager and Product Specialist, Arrayjet Ltd |
|---|---|
| Date / Time | October 14, 2014 / 14:00-17:00 |
| Venue | 2nd floor Seminar Room (#A207), iCeMS Main Building, Kyoto University
Directions |
| Flyer |  PDF (233KB) |
| Host | Institute for Integrated Cell-Material Sciences (iCeMS), Kyoto University |
| Co-Host | NPO Kyoto SMI, Scottish Development Interntational (SDI) |
| Registration | Required for the networking lunch. If you wish to attend, please send your name and affiliation, and phone number to tasada@icems.kyoto-u.ac.jp Deadline: Thu 02 October |
| Contact | Takashi Asada | tasada@icems.kyoto-u.ac.jp |